Today we are pleased to announce the release of @LabCentral's 2022 Impact Report detailing the influence of our 81 resident and 166 alumni companies on the local and national life sciences and biotech industry. Our impact was measured in terms of funding, patents, clinical trials, job creation, and our expanded facilities and programs from the past year. We are proud of our community's accomplishments and eager to share their success with the world.
Read the full report here: https://t.co/97PdkBnNLK
#WhereBiotechBegins #WeAreBioDiversity
🔊 Calling biotech entrepreneurs!
Join today’s @NCIsbir Development Center webinar (2:00-3:30 PM) for an overview of the PHS 2025-I Contract Solicitation. Learn about early-stage cancer tech funding & 13 NCI topics. Q&A session included. Register now: https://t.co/mY3LHC80ny
STARTING NOW: @JNJNews is at LabCentral talking all things Oncology. Featuring a presentation with follow up panels this is one you don't want to miss!
See agenda here: https://t.co/3UItAjJdJK
On #WorldBrainDay we're asking a question that came from our most recent conversation between @JFruehauf and @ksbosley.
Could #triculture systems like the one in the video below ultimately replace traditional #animalcell culture systems? 🧠🤔
Catch the full episode of The Dish on our Youtube channel!
It's here! The first full episode of our new video series, 'The Dish with Johannes' is out on our Youtube channel! 🧫🔬
Full episode here 👉 https://t.co/MZwFXUNH5c
In our premiere episode, @JFruehauf sits down with @ksbosley to hear more about her latest startup venture – DaCapo Brainscience
🫣 Sneak peek below! 🫣
Introducing ‘The Dish with Johannes’! Join LabCentral’s President, Johannes Fruehauf, as he dives into biotech's dynamic world. 🌟
From startups to investor decisions and industry leader support, hear stories shaping biotech's future. Tune in for insights from biotech pioneers! #innovation #biotech
Today we're pleased to announce the release of our 2023 Impact Report, detailing a decade of groundbreaking #innovation and economic growth for biotech and life sciences #startups at LabCentral!
To read to full report head to the link below! 👇👇
https://t.co/1CZYse29zC
Excited to announce the Diamond Ticket in partnership with @AstellasUS! We're looking to award one powerhouse biotech startup with private lab space at our LabCentral 238 location, a value of $500,000. Applications close April 5th!
Learn more below 👇👇
https://t.co/P2lcfo85jw
Incredible dialogue last night between @EllisKSean and @E_DeniseSimmons on the enduring systemic racism in our justice system & the struggles faced by exonerees long after release. Check out the work being done by the New England Innocence Project to get involved. #socialimpact
In honor of #WorldDiabetesDay, we're featuring one of our resident companies– i2o Therapeutics.
I2o aims to address type 2 diabetes through all-oral regimens & implantable therapies. This comes at a pivotal time, as experts say diabetes could impact 1.3 billion people by 2050.
And we're off! Today we're holding our first ever Leadership Summit, aptly titled "What's Next" 🤔💡
As our resident founders and CEOs navigate their biotech & life sciences startups, it seems like the question on many minds is, 'what's next?' Today, we've gathered expert speakers in an attempt to answer that question.
What do you wish you knew early in your startup journey?
#ResidentSuccess #LCWhatsNext #LCLeadershipSummit #WhereBiotechBegins #PuttingLifeInLifeSciences
Today LabCentral was taken on a food tour around the world with our 3rd annual #CulturalCelebration! Residents, sponsors and partners came together to represent 20 countries through food, drink and dress 🤩 Thank you to everyone who attended! Now, time for our #foodcoma 🥴
#Gallery1832 is back with another art reception –this time highlighting #sustainability 🌱 come celebrate our latest installation 'Catch & Release' sponosred by @Triumvirate
📅 Date: October 4th
🕕 Time: 4:30pm - 6:30pm
📍 Location: 700 Main St.
✉️ RSVP: https://t.co/OG02GZN0rl
We are proud to announce first patient dosing in a Phase 1a/b trial for NPX267, a monoclonal antibody targeting KIR3DL3, the inhibitory receptor for HHLA2, designed to reverse immune suppression in solid tumors.
Read more: https://t.co/g2vxqa9EbB.
When #Asimov's team needed access to an #HPLC system to confirm some last-minute data before a webinar, they contacted LabCentral for help.
Whether your #startup is a current resident, or has graduated into the alumni status – we're here to help empower #innovation
New art alert! 🎨 @smdselfmade, a collective of artists in the Greater Boston area, have taken over the walls of #Gallery1832 at LabCentral 238.
If you're in our 238 location, or at the new #BayerCoLab come check it out!
Have you heard about the new Bayer Co.Lab?
Designed to support #cellandgenetherapy entrepreneurs, the Bayer Co.Lab provides access to Bayer's extensive expertise and a state-of-the-art lab and office space (operated by yours truly 😉)
Apply here: https://t.co/sVgz73UYQ0